ketohexokinase

RefSeq NM_006488 (human), NM_008439 (mouse), NM_031855 (rat)

Also Known As:

ATP-D-fructose 1-phosphotransferase; Hepatic fructokinase; KHK protein, human; Khk protein, mouse; Khk protein, rat; ketohexokinase (fructokinase), human; ketohexokinase, mouse; ketohexokinase, rat

Networked: 41 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Phosphotransferases: 42769
      - Phosphotransferases (Alcohol Group Acceptor)
        Fructokinases
        ketohexokinase: 41

Experts

1.	Johnson, Richard J: 3 articles (02/2021 - 01/2018)
2.	Lanaspa, Miguel A: 3 articles (02/2021 - 01/2018)
3.	Fonseca, Kari R: 2 articles (07/2022 - 01/2022)
4.	Rodrigues, A David: 2 articles (07/2022 - 01/2022)
5.	Tess, David A: 2 articles (07/2022 - 01/2022)
6.	Varma, Manthena V S: 2 articles (07/2022 - 01/2022)
7.	Weng, Yan: 2 articles (07/2022 - 01/2022)
8.	Guo, Juanjuan: 2 articles (01/2022 - 01/2021)
9.	Hao, Zhiqiang: 2 articles (01/2022 - 01/2021)
10.	He, Jianping: 2 articles (01/2022 - 01/2021)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 01/01/2021 - "Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial." 01/01/2023 - "To assess the safety, tolerability and pharmacodynamics (PD) of the ketohexokinase inhibitor PF-06835919 in participants with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). " 07/02/2022 - "Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease." 04/01/2021 - "Increasing evidence highlights dietary fructose as a major driver of non-alcoholic fatty liver disease (NAFLD) pathogenesis, the majority of which is cleared on first pass through the hepatic circulation by enzymatic phosphorylation to fructose-1-phosphate via the ketohexokinase (KHK) enzyme. " 01/01/2022 - "The PG-HM suppressed ped-NAFLD through hepatic signalling pathways of 1) leptin-insulin (Akt/FOX-O1/SREBP-1c), 2) hypoxia-inflammation (HIF-1ɑ/VEGF, TNF-ɑ), 3) mitochondrial function (complexes I-V), 4) oxidative stress (MDA, GSH, SOD) and 5) glycolysis/gluconeogenesis/de novo lipogenesis (hexokinase, phosphofructokinase, ketohexokinase, aldehyde dehydrogenase). "
2.	Metabolic Diseases (Metabolic Disease) 10/12/2023 - "Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease."
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2023 - "Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study."
4.	Neoplasms (Cancer) 05/01/2011 - "Based on the GLUT5 specific transport and phosphorylation by ketohexokinase, 6-[(18)F]FDF may represent a novel radiotracer for PET imaging of GLUT5 and ketohexokinase-expressing tumors." 02/01/2006 - "The level of ketohexokinase activity in histological grade 3 RCC was 1.8-fold lower than that in grade 1 cancer. " 02/01/2006 - "Ketohexokinase activity in tumor stage pT3 RCC was 1.5-fold lower than in pT1 RCC. " 10/28/2020 - "From a therapeutic perspective, the ketohexokinase-A signaling pathway could be a potential target to prevent cancer metastasis." 01/01/2019 - "The metabolism-reprogramming marker ketohexokinase (KHK)-A and acetyl-CoA synthetase 2 (ACSS2) phosphorylation at S659 (ACSS2 pS659) play important roles in tumorigenesis and tumor development. "
5.	Hypoxia (Hypoxemia) 01/01/2022 - "Immunostaining, western blot and quantitative real-time reverse transcription PCR (qRT-PCR) were performed to detect the expression of glucose transporter 5 (GLUT5), ketohexokinase (KHK)-A and KHK-C in miR-155-/- and miR-155wt CFs under normoxia or hypoxia. " 01/01/2021 - "Furthermore, Gansu zokor brain exhibited enhanced fructose-driven glycolysis under hypoxia through increased expression of the GLUT5 fructose transporter and ketohexokinase (KHK), in addition to increased KHK enzymatic activity, and utilization of fructose; these changes did not occur in rat. " 01/01/2022 - "Interestingly, under all hypoxia conditions, Gansu zokor liver exhibited enhanced fructose-driven metabolism through increased expression of the GLUT5 fructose transporter, ketohexokinase (KHK), aldolase B (ALDOB), and aldolase C (ALDOC), as well as increased KHK enzymatic activity and fructose utilization. " 02/01/2004 - "Analysis of the metabolite contents in lamina and vein fractions of the leaf, and of the enzymes of carbohydrate oxidation indicate that the phloem-enriched veins of ketohexokinase-expressing leaves tend toward hypoxia and indicate a problem of phloem transport." 01/01/2021 - "MiRNAs also coordinated anaerobic glycolytic fuel sources, where hypoxia-upregulated miR-365 likely suppressed protein levels of ketohexokinase, the enzyme responsible for catalyzing the first committed step of fructose catabolism. "

Related Drugs and Biologics

1.	Fructose
2.	Enzymes
3.	fructose-1-phosphate
4.	Proteins (Proteins, Gene)
5.	Fructose-Bisphosphate Aldolase (Aldolase)
6.	fructokinase
7.	Facilitative Glucose Transport Proteins (Glucose Transporter)
8.	Phosphotransferases (Kinase)
9.	Sirtuin 1
10.	Insulin Receptor Substrate Proteins